Cargando…

Novel Therapeutics in Alzheimer's Disease

Detalles Bibliográficos
Autores principales:	Sabbagh, Marwan, Porsteinsson, Anton P., Nair, Anil, Adem, Abdu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320000/ https://www.ncbi.nlm.nih.gov/pubmed/22536534 http://dx.doi.org/10.1155/2012/207969

Ejemplares similares

New Acetylcholinesterase Inhibitors for Alzheimer's Disease
por: Mehta, Mona, et al.
Publicado: (2012)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

Is diabetes associated with increased pathological burden in Alzheimer's disease?
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2021)

Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer’s Disease and Related Disorders
por: Sabbagh, Marwan N.
Publicado: (2017)

Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
por: Tousi, Babak, et al.
Publicado: (2021)

APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline
por: Abushakra, Susan, et al.
Publicado: (2020)

Alzheimer’s disease beyond amyloid: strategies for future therapeutic interventions
por: Shi, Jiong, et al.
Publicado: (2020)

Alzheimer's Disease and Cognitive Frailty: Novel Therapeutic Technologies
por: D'Onofrio, Grazia, et al.
Publicado: (2016)

Novel therapeutic target against Alzheimer
por: LeBlanc, Andrea C.
Publicado: (2017)

Temporospatial components of brain ERPs as biomarkers for Alzheimer's disease
por: Chapman, Robert M., et al.
Publicado: (2018)

Editorial Introduction
por: Sabbagh, Marwan N.
Publicado: (2016)

Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012)

Potential Peripheral Biomarkers for the Diagnosis of Alzheimer's Disease
por: Patel, Seema, et al.
Publicado: (2011)

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011)

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Alzheimer's disease drug development pipeline: 2020
por: Cummings, Jeffrey, et al.
Publicado: (2020)

Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data
por: Sabbagh, Marwan N., et al.
Publicado: (2017)

Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease?
por: Lue, Lih-Fen, et al.
Publicado: (2012)

FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

Atypical PKC: therapeutic target for Alzheimer’s?
por: Farese, Robert V., et al.
Publicado: (2018)

BACE1: from biomarker to Alzheimer’s disease therapeutical target
por: Cervellati, Carlo, et al.
Publicado: (2021)

Longitudinal Effects of Metabolic Syndrome on Alzheimer and Vascular Related Brain Pathology
por: Lin, Feng, et al.
Publicado: (2014)

YAP: a novel target for Alzheimer's disease
por: Xu, Xingxing, et al.
Publicado: (2022)

Pharmacognostical Sources of Popular Medicine To Treat Alzheimer’s Disease
por: Kalász, Huba, et al.
Publicado: (2018)

Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer’s dementia?
por: Crum, Jana, et al.
Publicado: (2018)

Calcium Signalling in Alzheimer’s Disease: From Pathophysiological Regulation to Therapeutic Approaches
por: Chami, Mounia
Publicado: (2021)

Neuropathic pain: Mechanisms and therapeutic strategies
por: Petroianu, Georg A., et al.
Publicado: (2023)

5HT6 Antagonists in the Treatment of Alzheimer’s Dementia: Current Progress
por: Andrews, Megan, et al.
Publicado: (2018)

Differences in Cerebrospinal Fluid Biomarkers between Clinically Diagnosed Idiopathic Normal Pressure Hydrocephalus and Alzheimer’s Disease
por: Tsai, Andrew, et al.
Publicado: (2014)

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
por: Burstein, Aaron H, et al.
Publicado: (2014)

KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Patients
por: Malek-Ahmadi, Michael, et al.
Publicado: (2013)

The Cause of Alzheimer’s Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress
por: Decourt, Boris, et al.
Publicado: (2022)

Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease
por: Shineman, Diana W, et al.
Publicado: (2013)

Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
por: Tiwari, Sneham, et al.
Publicado: (2019)

A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation
por: Akil, Ayman, et al.
Publicado: (2015)

Neurobiologic Rationale for Treatment of Apathy in Alzheimer’s Disease With Methylphenidate
por: van Dyck, Christopher H., et al.
Publicado: (2020)

Development, Application, and Results from a Precision-medicine Platform that Personalizes Multi-modal Treatment Plans for Mild Alzheimer’s Disease and At-risk Individuals
por: Keine, Dorothy, et al.
Publicado: (2018)

Platelet BACE1 levels as a possible biomarker for Alzheimer’s disease
por: Decourt, Boris, et al.
Publicado: (2013)

Editorial: Novel Therapeutic Approaches in Inflammatory Bowel Diseases
por: Pallio, Giovanni
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7mb5u4oduo7qjt23src1ncap2m